Newsfile·2025-11-05 23:17Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 29, 2025 [3]. - The lawsuit alleges that DexCom made false statements regarding the reliability and safety of its G6 and G7 continuous glucose monitoring systems, which were not authorized by the FDA [5]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom's design changes to the G6 and G7 systems rendered them less reliable, posing health risks to users [5]. - It is alleged that the company overstated the enhancements and reliability of the G7 device while downplaying the severity of the issues related to the devices [5]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these misleading statements [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].